Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://www.nature.com/articles/s41571-023-00799-2.pdf
Reference244 articles.
1. Tilly, H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N. Engl. J. Med. 386, 351–363 (2022).
2. Phillips, T. et al. Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Blood 140, 9443–9445 (2022).
3. Olszewski, A. J. et al. Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and ≥65 years with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and ≥1 prior therapy: subgroup analysis of a phase Ib/II study. Blood 140, 3757–3759 (2022).
4. Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2022).
5. Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294–2308 (2022).
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lymphoma;PET Clinics;2024-10
2. Molecular biomarkers in classic Hodgkin lymphoma;Seminars in Hematology;2024-05
3. Dual-Layer Spectral Detector Computed Tomography Quantitative Parameters: A Potential Tool for Lymph Node Activity Determination in Lymphoma Patients;Diagnostics;2024-01-09
4. A hybrid few-shot multiple-instance learning model predicting the aggressiveness of lymphoma in PET/CT images;Computer Methods and Programs in Biomedicine;2024-01
5. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial;Clinical Cancer Research;2023-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3